## Introduction
Pancreas and islet cell transplantation represent the pinnacle of treatment for select patients with diabetes, offering the potential to restore physiological glucose regulation and achieve independence from exogenous insulin. However, the successful application of these life-altering therapies requires a sophisticated understanding that goes far beyond simple cell replacement. It demands a deep appreciation of the distinct [pathophysiology of diabetes](@entry_id:154025) types, the nuances of complex surgical procedures, and the formidable immunological challenges that threaten graft survival. This article provides a comprehensive journey through the world of beta-cell transplantation.

The first chapter, **"Principles and Mechanisms,"** lays the scientific groundwork, explaining the core rationale for transplantation, comparing the modalities of whole-organ versus isolated islet grafts, and detailing the critical biological hurdles of early graft injury and the immune response. The second chapter, **"Applications and Interdisciplinary Connections,"** bridges this science to practice by exploring intricate clinical decision-making, patient selection strategies, and the multidisciplinary management of transplant recipients, highlighting connections to immunology, infectious disease, and bioengineering. Finally, the **"Hands-On Practices"** chapter allows you to apply these concepts through practical exercises in islet dosing, [pharmacokinetic modeling](@entry_id:264874), and health economic analysis. This structured approach will equip you with the foundational knowledge needed to understand and evaluate this advanced therapeutic field.

## Principles and Mechanisms

### The Fundamental Rationale: Replacing Beta-Cell Mass

The primary goal of pancreas and islet transplantation is to restore endogenous, regulated insulin secretion in individuals with diabetes. However, the rationale for this intervention is critically dependent on the underlying pathophysiology of the specific type of diabetes. A precise understanding of the distinction between type 1 and [type 2 diabetes](@entry_id:154880) mellitus is therefore the foundational principle guiding patient selection for these advanced therapies.

#### Pathophysiological Basis for Transplantation in Type 1 Diabetes

**Type 1 Diabetes Mellitus (T1DM)** is an organ-specific autoimmune disease characterized by the selective and near-total destruction of insulin-producing beta cells within the pancreatic islets of Langerhans. The clinical presentation of T1DM is a direct consequence of this absolute insulin deficiency. The immunological basis for this destruction is a breakdown in self-tolerance, leading the patient's own adaptive immune system to recognize and eliminate beta cells as if they were foreign invaders.

The process is orchestrated by T lymphocytes. Professional antigen-presenting cells (APCs), such as [dendritic cells](@entry_id:172287), process and present beta-cell-specific autoantigens—peptides derived from proteins like **[glutamic acid decarboxylase](@entry_id:164202) 65 kilodalton (GAD65)**, **insulinoma-associated protein 2 (IA-2)**, **zinc transporter 8 (ZnT8)**, and insulin itself. These peptides are presented on **Major Histocompatibility Complex (MHC) class II** molecules (encoded by specific **Human Leukocyte Antigen (HLA)** genes strongly associated with T1DM) to $CD4^{+}$ helper T cells. Once activated, these helper T cells provide "help" to autoreactive B cells, which then produce the characteristic autoantibodies used as diagnostic markers, and, crucially, license $CD8^{+}$ cytotoxic T lymphocytes (CTLs). These CTLs are the primary executioners of beta-cell destruction. They recognize [beta-cell](@entry_id:167727) autoantigens presented on **MHC class I** molecules directly on the surface of beta cells and kill them via mechanisms such as the [perforin](@entry_id:188656)/granzyme and Fas-Fas ligand pathways.

The clinical hallmark of this process is an absolute deficiency of insulin secretion, which can be quantified by measuring **C-peptide**. C-peptide is cleaved from the proinsulin molecule during insulin synthesis and is co-secreted in equimolar amounts with insulin. An undetectable or severely reduced C-peptide level (e.g., $0.1$ ng/mL) in the presence of hyperglycemia confirms the near-total loss of functional beta-cell mass. Because the core deficit in T1DM is the physical absence of insulin-producing cells, the therapeutic logic of transplantation is clear and direct: it is a cell replacement strategy. By providing a new source of functional beta cells—either as a vascularized whole-organ pancreas graft or as a preparation of isolated islets—it is possible to restore endogenous insulin production and normalize glycemic control, provided the recipient's immune system is suppressed to prevent both rejection of the foreign graft (**alloimmunity**) and recurrence of the original autoimmune disease [@problem_id:5161664].

#### The Limits of Transplantation in Severe Insulin Resistance

In stark contrast, **Type 2 Diabetes Mellitus (T2DM)** is primarily a metabolic disorder characterized by two core defects: **peripheral insulin resistance** and a progressive, relative decline in beta-cell function. In many patients with T2DM, especially those with obesity, the primary lesion is the inability of target tissues—liver, muscle, and adipose tissue—to respond effectively to insulin. This is due to defects in the post-receptor [insulin signaling pathway](@entry_id:178355), such as impaired phosphorylation of [insulin receptor](@entry_id:146089) substrates (IRS) and subsequent blunting of the [phosphoinositide 3-kinase](@entry_id:202373) (PI3K)–AKT pathway. A critical consequence of this signaling defect is the failure of the glucose transporter **GLUT4** to translocate to the cell surface in muscle and fat, severely impairing glucose uptake.

Unlike T1DM patients, individuals with T2DM, particularly in the earlier stages, often exhibit normal or even elevated C-peptide levels. This indicates that their pancreas is producing substantial amounts of insulin, but it is insufficient to overcome the profound resistance. A patient requiring very high doses of exogenous insulin (e.g., $1.0-1.5$ units/kg/day) exemplifies a state of severe [insulin resistance](@entry_id:148310). In such a scenario, transplanting a standard [beta-cell](@entry_id:167727) mass, such as a single-donor islet graft, is generally not a rational therapeutic option. A typical islet graft provides a physiological number of islets, but this normal [beta-cell](@entry_id:167727) mass would be placed into a metabolic environment demanding a supraphysiological level of insulin secretion. The graft would be subjected to the same metabolic stressors (glucotoxicity, [lipotoxicity](@entry_id:156126)) that contributed to the dysfunction of the patient's native beta cells, predisposing it to rapid failure. Overcoming the metabolic demand of severe [insulin resistance](@entry_id:148310) would require an unrealistically large and thus clinically unfeasible beta-cell mass [@problem_id:5161664]. Therefore, pancreas and islet transplantation are primarily indicated for patients with absolute or near-absolute insulin deficiency, a condition typified by T1DM.

### Therapeutic Modalities: Whole Organ vs. Islet Cells

Once a patient is deemed a suitable candidate for beta-cell replacement, a choice must be made between two primary modalities: whole-organ pancreas transplantation and isolated islet cell transplantation. Each has distinct surgical approaches, indications, and associated challenges.

#### Whole-Organ Pancreas Transplantation

This modality involves transplanting the entire pancreas, or a segment of it, along with a portion of the donor duodenum and its associated blood supply. The graft is typically placed **heterotopically** in the recipient's iliac fossa, and the native pancreas is left in situ. Vascular anastomoses are made to the recipient's iliac vessels.

##### Surgical Strategies and Indications: PTA, SPK, and PAK

While the fundamental surgical technique for implanting the pancreas graft remains largely consistent, the clinical context and timing of the operation define three distinct categories of pancreas transplantation [@problem_id:5161629].

- **Simultaneous Pancreas-Kidney (SPK) Transplantation:** This is the most common type of pancreas transplant. It is performed in patients with T1DM who also have end-stage renal disease (ESRD) secondary to [diabetic nephropathy](@entry_id:163632). Both the pancreas and a kidney from the same deceased donor are transplanted during the same operation. The kidney is typically placed in one iliac fossa and the pancreas in the contralateral fossa. The primary goals are to treat both uremia and diabetes, thereby improving both survival (from the kidney transplant) and quality of life while preventing recurrent [diabetic nephropathy](@entry_id:163632) in the new kidney. The presence of the kidney graft provides a reliable "sentinel" for rejection, as a rise in serum creatinine often precedes evidence of pancreas rejection. This robust rejection monitoring justifies potent immunosuppression regimens.

- **Pancreas After Kidney (PAK) Transplantation:** This procedure is performed in a diabetic patient who has previously received a kidney transplant for ESRD. The primary goal is to address the metabolic derangements of diabetes to improve quality of life and potentially protect the existing kidney allograft from long-term diabetic complications. The risk-benefit calculus is different from SPK, as the patient is already on immunosuppression, but the incremental survival benefit of adding a pancreas is less certain. A critical consideration is preserving the function of the pre-existing kidney graft.

- **Pancreas Transplant Alone (PTA):** This is the least common type and is performed in diabetic patients who have preserved native kidney function. The indication is not organ failure but rather severe, life-threatening metabolic instability (e.g., recurrent severe hypoglycemia, hypoglycemic unawareness) that cannot be managed with intensive insulin therapy. Because there is no immediate survival benefit as there is with a kidney transplant for ESRD, the risks of major surgery and lifelong immunosuppression must be carefully weighed against the quality-of-life benefits. Immunosuppression strategies may be tailored to minimize long-term toxicity, for instance, through steroid avoidance protocols [@problem_id:5161629].

##### Exocrine Drainage: A Key Surgical Decision

The transplanted pancreas produces not only endocrine hormones (insulin) but also approximately one liter per day of alkaline, enzyme-rich exocrine juice. A critical surgical decision is how to manage this exocrine output. This is accomplished by performing an anastomosis using the segment of donor duodenum that is harvested with the pancreas graft [@problem_id:5161689].

- **Enteric Drainage:** This is the current standard and most physiological approach. The donor duodenal segment is anastomosed directly to the recipient's small intestine (e.g., a **duodenojejunostomy**). This returns the pancreatic juice and bicarbonate to the gastrointestinal tract, preserving normal [digestive physiology](@entry_id:150186) and avoiding metabolic disturbances. However, this approach carries risks of intra-abdominal complications, including anastomotic leak, abscess formation, and bleeding. Rejection monitoring is more challenging, relying on serum markers and, if necessary, endoscopic biopsy of the graft duodenal mucosa.

- **Bladder Drainage:** Historically, a common technique was to anastomose the donor duodenum to the recipient's urinary bladder (**duodenocystostomy**). The primary advantage of this approach was the ability to non-invasively monitor for rejection by measuring amylase levels in the urine; a drop in urinary amylase often signals graft inflammation or rejection. However, bladder drainage is associated with significant complications. The diversion of enzyme-rich fluid into the urinary tract can cause chemical cystitis, urethritis, and hematuria. More importantly, it results in the continuous loss of large amounts of bicarbonate in the urine, leading to a chronic, non-anion gap **metabolic acidosis**.

For example, consider a patient with bladder drainage losing $1.0$ L/day of pancreatic juice with a bicarbonate concentration of $90$ mEq/L. This represents a daily loss of $90$ mEq of bicarbonate. In a patient with an extracellular fluid volume of $14$ L, this loss would cause the plasma bicarbonate concentration to fall by approximately $\Delta[\text{HCO}_3^-] = \frac{90 \text{ mEq}}{14 \text{ L}} \approx 6.4$ mEq/L over 24 hours. If the baseline bicarbonate was $24$ mEq/L, the new concentration would be approximately $17.6$ mEq/L. Using the Henderson-Hasselbalch equation, $\text{pH} = 6.1 + \log_{10}([\text{HCO}_3^-]/(0.03 \cdot P_{\text{CO}_2}))$, and assuming a constant arterial carbon dioxide tension ($P_{\text{CO}_2}$) of $40$ mmHg, the resulting pH would be approximately $7.27$, a significant acidosis that requires oral bicarbonate supplementation. Due to these complications, bladder drainage is now rarely performed and is reserved for select cases [@problem_id:5161689].

#### Islet Cell Transplantation: A Cellular Therapy

Islet cell transplantation is a less invasive alternative to whole-organ transplantation. Instead of a major open surgery, it involves infusing isolated islets from a deceased donor pancreas, typically into the recipient's portal vein. The islets then lodge in the liver sinusoids and, upon engraftment, begin to secrete insulin directly into the portal circulation.

##### From Organ to Cells: The Islet Isolation Process

The success of islet transplantation is critically dependent on the ability to isolate a large number of pure, viable, and functional islets from a donor pancreas. This is a complex, multi-step laboratory process [@problem_id:5161695].

1.  **Enzymatic Digestion:** The process begins by perfusing a cocktail of enzymes, primarily **collagenase** and a neutral protease, into the pancreatic duct. The goal is to selectively hydrolyze the collagen-rich extracellular matrix that holds the pancreatic tissue together. This must be done under carefully controlled conditions (temperature, time) to digest the matrix connecting islets to the exocrine tissue without damaging the islets' own delicate structure and basement membrane.

2.  **Mechanical Dissociation:** After enzymatic digestion has weakened the tissue, gentle mechanical agitation, often in a specialized device like a Ricordi chamber, is applied. This imposes a controlled **shear stress** ($\tau$) on the tissue, sufficient to break the remaining parenchymal bridges and liberate the islets. The force must be kept below the threshold that would cause architectural disruption or fragmentation of the islets themselves.

3.  **Density-Gradient Purification:** The resulting tissue digest is a [heterogeneous mixture](@entry_id:141833) of intact islets, islet fragments, and exocrine (acinar) tissue. The final step is to purify the islets. This is achieved by **[isopycnic centrifugation](@entry_id:164974)** on a continuous density gradient. This technique exploits the fact that islets have a slightly lower **[buoyant density](@entry_id:183522)** ($\rho_{\text{islet}}$) than the much more abundant acinar tissue ($\rho_{\text{acinar}}$). When centrifuged, the islets settle into a distinct band in the gradient, separated from the denser exocrine debris, allowing for their collection and enrichment.

##### Quantifying the Dose: Islet Equivalents (IEQ)

Islet preparations contain islets of varying sizes, from small clusters to large aggregates. A simple count of islets would be a poor measure of the transplanted endocrine mass. Therefore, the dose is standardized using the concept of an **Islet Equivalent (IEQ)**. One IEQ is defined as the volume of a single spherical islet with a diameter of $150 \, \mu\text{m}$. The total IEQ of a preparation is calculated by summing the volume of each individual islet (or islets within a size bin) and normalizing it to this reference volume. The formula for the IEQ of a single islet of diameter $d$ is $\text{IEQ} = (d/150)^3$. Thus, an islet with a diameter of $200 \, \mu\text{m}$ contributes significantly more than one IEQ, while an islet with a diameter of $100 \, \mu\text{m}$ contributes significantly less.

The final transplant dose is reported as **IEQ per kilogram of recipient body weight (IEQ/kg)**. This dosing strategy is based on fundamental [physiological scaling](@entry_id:151127). IEQ quantifies the transplanted endocrine mass, which must be sufficient to meet the recipient's metabolic needs. These needs, along with the capacity of the liver to receive and engraft the islets, scale approximately with the recipient's body mass. Dosing per kilogram thus standardizes the therapeutic [beta-cell](@entry_id:167727) mass relative to the individual's metabolic demand and the size of the engraftment site [@problem_id:5161674].

### Physiological Restoration and Early Graft Injury

The ultimate goal of transplantation is to restore not just insulin production, but physiologic glucose regulation. However, the transplanted tissue, whether a whole organ or isolated cells, faces immediate and significant biological insults that can compromise its function and survival.

#### Restoring Physiological Glycemic Control

Normal glucose tolerance is not merely about the presence of insulin, but about the timing and location of its release. A key feature of a healthy pancreatic response to a meal is a robust **first-phase insulin secretion**. This is a rapid pulse of insulin, released from pre-formed granules within minutes of a rise in blood glucose. This early surge creates a transiently high insulin concentration in the portal vein.

This high portal insulin level has two critical, immediate effects: it acts on the liver to potently **suppress hepatic glucose production (HGP)**, and it "primes" peripheral tissues like muscle for subsequent glucose uptake. The failure to suppress HGP promptly is a major reason for postprandial hyperglycemia. In T1DM, this first-[phase response](@entry_id:275122) is absent. When insulin is delivered by subcutaneous injection, its absorption is slow and it reaches the liver via the systemic circulation, failing to replicate the sharp, high-concentration portal signal.

Theoretically, transplantation can restore this crucial physiological mechanism. Any graft configuration that delivers secreted insulin directly into the portal circulation—such as **intrahepatic islet transplantation** or a **whole-pancreas graft with portal venous drainage**—is capable of recreating the first-phase insulin pulse and the steep hepatic-to-peripheral insulin gradient. In contrast, a pancreas graft with systemic venous drainage (anastomosed to the iliac vein) releases insulin into the general circulation, where it is diluted before reaching the liver, thus blunting its ability to rapidly suppress HGP. The restoration of this first-phase hepatic signaling is a central mechanistic advantage of portal-drained grafts in achieving truly physiologic glucose control [@problem_id:5161750].

#### Mechanisms of Early Graft Injury

The period immediately following transplantation is fraught with peril for the graft, which is highly vulnerable to non-immunological injury. The nature of this injury differs significantly between whole-organ and islet grafts.

##### Ischemia-Reperfusion Injury (IRI) in Whole-Organ Grafts

A vascularized pancreas graft inevitably undergoes a period of **ischemia** (lack of blood flow) during procurement and preservation, followed by **reperfusion** upon transplantation. This process, known as [ischemia-reperfusion injury](@entry_id:176336) (IRI), triggers a cascade of damaging events. During ischemia, cellular ATP is depleted, leading to the accumulation of metabolites like hypoxanthine. Upon reperfusion, the reintroduction of oxygen leads to a burst of **reactive oxygen species (ROS)** from two main sources: [mitochondrial electron transport chain](@entry_id:165312) "leak" and the action of the enzyme xanthine oxidase on accumulated hypoxanthine.

This oxidative stress causes widespread cellular damage, particularly to the vascular endothelium. The injured endothelium becomes "activated," upregulating adhesion molecules (e.g., P-selectin, E-selectin, ICAM-1) via pathways like NF-$\kappa$B. This promotes the adhesion of circulating leukocytes, which then infiltrate the graft and amplify the inflammatory response, leading to post-transplant pancreatitis. The damaged endothelium also becomes pro-thrombotic, expressing **tissue factor (TF)**, which initiates the coagulation cascade and can lead to **microthrombosis** within the graft's small vessels, further compromising blood flow and potentially causing early graft thrombosis [@problem_id:5161682].

##### The Unique Challenge of Islet Grafts: Instant Blood-Mediated Inflammatory Reaction (IBMIR)

When isolated islets are infused into the portal vein, they face a different, but equally formidable, challenge known as the **Instant Blood-Mediated Inflammatory Reaction (IBMIR)**. This is a rapid, thrombo-inflammatory process that occurs when the islets come into direct contact with recipient blood. Islets, particularly those in less pure preparations, express high levels of **tissue factor (TF)** on their surface. This immediately triggers the coagulation cascade, leading to a burst of thrombin generation and the formation of a fibrin clot around the islets, physically entrapping them. Simultaneously, the islet surfaces activate the **[complement system](@entry_id:142643)**.

This combined activation of coagulation and complement unleashes a potent inflammatory response. Recipient platelets are activated, and inflammatory cells, particularly neutrophils, are rapidly recruited to the site. These activated neutrophils undergo a "[respiratory burst](@entry_id:183580)," releasing massive amounts of ROS via the **NADPH oxidase** enzyme. The entire cascade—thrombosis, [complement activation](@entry_id:197846), and leukocyte infiltration—can destroy a significant fraction (often over 50%) of the transplanted islets within minutes to hours of infusion, representing a major barrier to the success of clinical islet transplantation [@problem_id:5161682].

##### The Impact of Donor Quality on Early Injury

The severity of these early injury processes is heavily influenced by the quality of the donor organ. Several donor factors are known to increase the risk of complications like graft thrombosis and post-transplant pancreatitis by exacerbating the underlying mechanisms of IRI [@problem_id:5161668].

- **Older Donor Age (e.g.,  50 years):** Older organs have underlying microvascular [atherosclerosis](@entry_id:154257) and endothelial senescence, making them more susceptible to thrombotic events and less resilient to ischemic injury.
- **High Donor BMI (e.g.,  30 kg/m²):** Fatty infiltration of the pancreas (steatosis) is associated with a pro-inflammatory state and impaired microcirculation, which worsens both pancreatitis and thrombosis risk upon reperfusion.
- **Donation after Circulatory Death (DCD):** DCD organs suffer a period of uncontrolled warm ischemia, which causes severe endothelial and acinar cell injury, dramatically amplifying IRI and leading to a very high risk of both thrombosis and pancreatitis.
- **Prolonged Cold Ischemia Time (e.g.,  12 hours):** Extended cold storage leads to progressive endothelial damage and metabolic derangement in acinar cells, increasing the risk of microvascular no-reflow, thrombosis, and [zymogen](@entry_id:182731) dysregulation that precipitates pancreatitis.

Careful donor selection is therefore a critical first step in mitigating the risk of early graft failure.

### The Immunological Challenge: Rejection and Recurrence

Even if a graft survives the initial perioperative period, it faces a lifelong threat from the recipient's immune system. Successful long-term function requires navigating the complex immunology of transplantation.

#### The Foundation of Transplant Immunology

The immune system's ability to distinguish "self" from "non-self" is mediated by **Human Leukocyte Antigens (HLA)**. The core principle of [transplant rejection](@entry_id:175491) is the recognition of the donor's foreign HLA molecules by the recipient's immune system. Managing this response requires a sophisticated set of immunological tools [@problem_id:5161691].

- **HLA Matching:** This involves comparing the HLA types of the donor and recipient. A closer match reduces the "antigenic disparity" and generally lowers the risk of rejection.

- **Sensitization and Panel Reactive Antibody (PRA/cPRA):** A recipient may be "sensitized," meaning they have pre-existing antibodies against foreign HLA antigens from prior exposures like pregnancy, blood transfusions, or a previous transplant.
    - **Panel Reactive Antibody (PRA)** is a laboratory test that measures the percentage of a random panel of donor cells that the recipient's serum reacts with.
    - **Calculated Panel Reactive Antibody (cPRA)** is a more precise, modern metric. Based on the specific anti-HLA antibodies a recipient has, it calculates the percentage of the general donor population with which they would be incompatible. A high cPRA (e.g., 70%) indicates the patient is highly sensitized and finding a compatible donor will be difficult.

- **Crossmatching:** This is the final, critical test performed just before transplantation, mixing the potential donor's cells with the recipient's serum to detect **[donor-specific antibodies](@entry_id:187336) (DSAs)**.
    - **Complement-Dependent Cytotoxicity (CDC) Crossmatch:** A positive CDC crossmatch indicates the presence of potent, complement-fixing DSAs. This signifies an extremely high risk of **[hyperacute rejection](@entry_id:196045)**—an immediate, catastrophic destruction of the graft—and is an absolute contraindication for vascularized [organ transplantation](@entry_id:156159).
    - **Flow Cytometry Crossmatch (FCXM):** This is a more sensitive test that can detect lower levels of DSAs, including those that do not fix complement. A negative CDC but positive FCXM indicates a significant, but not absolute, risk of early **[antibody-mediated rejection](@entry_id:204220) (AMR)** and requires careful risk assessment and often enhanced immunosuppression.

#### Differentiating Causes of Graft Dysfunction

When a transplanted pancreas or islet graft begins to fail months or years after transplantation (evidenced by rising insulin requirements and declining C-peptide), it is critical to determine the underlying cause. In a T1DM recipient, two primary immunological processes must be distinguished: alloimmune rejection and recurrent autoimmunity [@problem_id:5161722].

- **Alloimmune Rejection:** This is an immune attack directed at the foreign **donor HLA antigens** on the graft. It can be T-cell mediated (diagnosed by lymphocytic infiltrates on biopsy) or antibody-mediated. Antibody-mediated rejection is characterized by the presence of circulating **[donor-specific antibodies](@entry_id:187336) (DSAs)** and often by the deposition of complement component **C4d** in the graft's microvasculature, a footprint of antibody-mediated attack. Monitoring for alloimmunity involves periodic screening for new or rising DSA levels and, in the case of a whole-organ pancreas, performing a graft biopsy for definitive diagnosis. For islet grafts, which cannot be biopsied, a diagnosis of alloimmunity is inferred from the combination of graft dysfunction and the emergence of DSAs.

- **Recurrent Autoimmunity:** This is a recurrence of the original T1DM, where the recipient's autoimmune response redirects itself against the new beta cells in the transplanted graft. The targets are not the foreign donor HLA, but rather the beta-cell **self-antigens** (e.g., GAD65, IA-2). This process is characterized by the reappearance or a significant rise in the titers of beta-cell specific autoantibodies. In this case, DSAs would be absent, and there would be no C4d deposition. Monitoring involves serial measurement of the panel of beta-cell autoantibodies in conjunction with sensitive functional tests of beta-cell mass, like a mixed-meal tolerance test.

Distinguishing between these two processes is paramount, as they require different therapeutic strategies. Alloimmune rejection is treated by augmenting general immunosuppression to target the anti-donor response, whereas managing recurrent autoimmunity may involve therapies aimed more specifically at the autoreactive arms of the immune system.